亚宝药业：拟8719万元出售太原制药62%股权

Core Viewpoint - The company, Yabao Pharmaceutical (600351.SH), announced the sale of a 62% stake in its subsidiary Taiyuan Pharmaceutical to Tongxiang Technology for a transaction price of 87.1887 million yuan [1] Group 1: Transaction Details - After the transaction, Tongxiang Technology will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the consolidated financial statements following the completion of the transaction [1] - The transaction does not constitute a related party transaction or a major asset restructuring, and it does not require approval from the shareholders' meeting [1] Group 2: Counterparty and Risks - The counterparty, Tongxiang Technology, is deemed capable of fulfilling the contractual obligations [1] - There exists a risk that the counterparty may not be able to timely pay the agreed transfer price for the equity stake [1]